Support for your patients every step of the way
A free supply of ZEPOSIA for up to 24 months to qualified, commercially insured patients who are at risk of an interruption in therapy
ECG=electrocardiogram; VZV=varicella-zoster virus.
dHome visits for initial routine medical tests are not available to people enrolled in Medicare, Medicaid, or other federal or state healthcare programs, or to people living in Rhode Island.
eThe Bridge Program is available at no cost for eligible commercially insured, on-label diagnosed patients if there is a delay in determining whether commercial prescription coverage is available, and is not contingent on any purchase requirement, for up to 24 months (dispensed in 30-day increments). The Bridge Program is not available to patients who have prescription insurance coverage through Medicare, Medicaid, or any other federal or state program, or MI residents, and is available for no more than 12 months to patients in MA, MN, and RI. Appeal of any prior authorization denial must be made within 90 days or as per payer guidelines, to remain in the Program. Eligibility will be re-verified in January for patients continuing into the following year, and may be at other times during Program participation. Offer is not health insurance, and may be modified or discontinued at any time without notice. Once coverage is approved by the patient’s commercial insurance plan, the patient will no longer be eligible. Other limitations may apply.
fDepending on insurance coverage and where the full cost is not covered by patient's insurance, eligible patients may receive a prescription benefit offer for out-of-pocket drug costs and pay as little as $0 per prescription, as well as a medical assessment benefit offer for out-of-pocket costs for the initial blood tests, ECG screening, and eye exam. Maximum savings limit applies; patient out-of-pocket expenses may vary. This program is not health insurance. Offer not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. Please click here for Program Terms, Conditions, and Eligibility Criteria.
Reference: 1. ZEPOSIA. Prescribing Information. Bristol-Myers Squibb Company; 2021.
Dosing, Initiation, and Patient Support Guide
Provides information on how to initiate treatment with ZEPOSIA, and education on the patient support offered to assist with the process
Available for your patients who forget to sign the ZEPOSIA Start Form. BMS eSign enables your patients to electronically sign through www.BMSesign.com
Baseline Testing Clearance Form
Used by ZEPOSIA 360 Support™ clinical partners to verify that a patient’s baseline tests have been reviewed by their prescriber and that they are able to start therapy
Access and Reimbursement Guide
Provides information on the process for accessing ZEPOSIA from initiation to delivery, coverage authorizations and appeals, and patient support offered by ZEPOSIA 360 SupportTM
Specialty Pharmacy Resource
Provides a quick overview of the benefits of using specialty pharmacies (SPs) and a list of SPs ready to handle ZEPOSIA prescriptions
ZEPOSIA Portal Assist
Provides an outline of how to enroll and manage patients using the ZEPOSIA portal
ZEPOSIA In-Home Support Overview
Provides a brief overview of in-home support available to patients
Overview of support available through CoverMyMeds® to enroll patients in ZEPOSIA 360 SupportTM and assist with access
Provides your patients with an overview of clinical study results, safety and support information for ZEPOSIA
Patient Getting Started Brochure
Provides a comprehensive guide to your patients about getting started on ZEPOSIA
ZEPOSIA UC Patient Profiles
Helps identify which of your patients are potentially appropriate for ZEPOSIA
Tyramine and ZEPOSIA Food and Drug Interaction Information
A helpful list of foods and beverages that are high in tyramine (150 mg or more)—a compound that should be avoided if your patients are taking ZEPOSIA